
Ballard Spahr says the Hikma v. Amarin decision makes it harder for brand-name drugmakers to sue over "skinny label" generics — a shift likely to speed generic competition and lower costs for patients
Do noncompetes have a future considering the courts seem to have a poor opinion of them?
The FTC banned noncompete agreements nationwide, but that decision is being
Medical Economics spoke with Emma Schuering, JD, of the



